Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

Corey L.; Gilbert P. B.; Juraska M.; Montefiori D. C.; Morris L.; Karuna S. T.; Edupuganti S.; Mgodi N. M.; deCamp A. C.; Rudnicki E.; Huang Y.; Gonzales P.; Cabello R.; Orrell C.; Lama J. R.; Laher F.; Lazarus E. M.; Sanchez J.; Frank I.; Hinojosa J.; Sobieszczyk M. E.; Marshall K. E.; Mukwekwerere P. G.; Makhema J.; Baden L. R.; Mullins J. I.; Williamson C.; Hural J.; McElrath M. J.; Bentley C.; Takuva S.; Lorenzo M. M. Gomez; Burns D. N.; Espy N.; Randhawa A. K.; Kochar N.; Piwowar-Manning E.; Donnell D. J.; Sista N.; Andrew P.; Kublin J. G.; Gray G.; Ledgerwood J. E.; Mascola J. R.; Cohen M. S.

首页> 外文期刊>The New England journal of medicine >Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

【24h】

Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

机译：两种随机试验中和抗体以预防HIV-1采购

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

BACKGROUND

机译：出身背景

著录项

来源
《The New England journal of medicine》 |2021年第11期|共12页
作者
Corey L.; Gilbert P. B.; Juraska M.; Montefiori D. C.; Morris L.; Karuna S. T.; Edupuganti S.; Mgodi N. M.; deCamp A. C.; Rudnicki E.; Huang Y.; Gonzales P.; Cabello R.; Orrell C.; Lama J. R.; Laher F.; Lazarus E. M.; Sanchez J.; Frank I.; Hinojosa J.; Sobieszczyk M. E.; Marshall K. E.; Mukwekwerere P. G.; Makhema J.; Baden L. R.; Mullins J. I.; Williamson C.; Hural J.; McElrath M. J.; Bentley C.; Takuva S.; Lorenzo M. M. Gomez; Burns D. N.; Espy N.; Randhawa A. K.; Kochar N.; Piwowar-Manning E.; Donnell D. J.; Sista N.; Andrew P.; Kublin J. G.; Gray G.; Ledgerwood J. E.; Mascola J. R.; Cohen M. S.;
展开▼
作者单位

Fred Hutchinson Canc Res Ctr Vaccine &

Infect Dis Div 1100 Fairview Ave N Seattle WA 98109 USA;

Fred Hutchinson Canc Res Ctr Vaccine &

Infect Dis Div 1100 Fairview Ave N Seattle WA 98109 USA;

Fred Hutchinson Canc Res Ctr Vaccine &

Infect Dis Div 1100 Fairview Ave N Seattle WA 98109 USA;

Duke Univ Med Ctr Duke Human Vaccine Inst Durham NC 27706 USA;

Univ Witwatersrand Natl Inst Communicable Dis Natl Hlth Lab Serv Johannesburg South Africa;

Fred Hutchinson Canc Res Ctr Vaccine &

Infect Dis Div 1100 Fairview Ave N Seattle WA 98109 USA;

Emory Univ Dept Med Div Infect Dis Atlanta GA 30322 USA;

Univ Zimbabwe Coll Hlth Sci Clin Trials Res Ctr Harare Zimbabwe;

Fred Hutchinson Canc Res Ctr Vaccine &

Infect Dis Div 1100 Fairview Ave N Seattle WA 98109 USA;

Fred Hutchinson Canc Res Ctr Vaccine &

Infect Dis Div 1100 Fairview Ave N Seattle WA 98109 USA;

Fred Hutchinson Canc Res Ctr Vaccine &

Infect Dis Div 1100 Fairview Ave N Seattle WA 98109 USA;

Hosp Nacl Mayo Serv Enfermedades Infecciosas &

Trop Lima Peru;

Asociac Civil Via Libre Lima Peru;

Univ Cape Town Dept Med Desmond Tutu HIV Ctr Cape Town South Africa;

Asociac Civil Impacta Salud &

Educ Lima Peru;

Univ Witwatersrand Fac Hlth Sci Perinatal HIV Res Unit Johannesburg South Africa;

Univ Witwatersrand Fac Hlth Sci Perinatal HIV Res Unit Johannesburg South Africa;

Univ Nacl Mayor San Marcos Ctr Invest Tecnol Biomed &

Medioambientales Lima Peru;

Univ Penn Div Infect Dis Perelman Sch Med Philadelphia PA 19104 USA;

Assoc Civil Selva Amazon Clin Res Site Iquitos Peru;

Columbia Univ Dept Med Irving Med Ctr Div Infect Dis New York NY USA;

Fred Hutchinson Canc Res Ctr Vaccine &

Infect Dis Div 1100 Fairview Ave N Seattle WA 98109 USA;

Univ Zimbabwe Coll Hlth Sci Clin Trials Res Ctr Harare Zimbabwe;

Botswana Harvard AIDS Inst Gaborone Botswana;

Harvard Med Sch Brigham &

Womens Hosp Boston MA 02115 USA;

Univ Washington Dept Global Hlth Seattle WA 98195 USA;

Univ Cape Town Div Med Virol Cape Town South Africa;

Fred Hutchinson Canc Res Ctr Vaccine &

Infect Dis Div 1100 Fairview Ave N Seattle WA 98109 USA;

Fred Hutchinson Canc Res Ctr Vaccine &

Infect Dis Div 1100 Fairview Ave N Seattle WA 98109 USA;

Fred Hutchinson Canc Res Ctr Vaccine &

Infect Dis Div 1100 Fairview Ave N Seattle WA 98109 USA;

Fred Hutchinson Canc Res Ctr Vaccine &

Infect Dis Div 1100 Fairview Ave N Seattle WA 98109 USA;

NIAID Vaccine Res Program Div Aids NIH Rockville MD USA;

NIAID Prevent Sci Program Div Aids NIH 9000 Rockville Pike Bethesda MD 20892 USA;

Fred Hutchinson Canc Res Ctr Vaccine &

Infect Dis Div 1100 Fairview Ave N Seattle WA 98109 USA;

Fred Hutchinson Canc Res Ctr Vaccine &

Infect Dis Div 1100 Fairview Ave N Seattle WA 98109 USA;

Fred Hutchinson Canc Res Ctr Vaccine &

Infect Dis Div 1100 Fairview Ave N Seattle WA 98109 USA;

Johns Hopkins Univ Sch Med Baltimore MD USA;

Fred Hutchinson Canc Res Ctr Vaccine &

Infect Dis Div 1100 Fairview Ave N Seattle WA 98109 USA;

FHI 360 Durham NC USA;

FHI 360 Durham NC USA;

Fred Hutchinson Canc Res Ctr Vaccine &

Infect Dis Div 1100 Fairview Ave N Seattle WA 98109 USA;

Fred Hutchinson Canc Res Ctr Vaccine &

Infect Dis Div 1100 Fairview Ave N Seattle WA 98109 USA;

NIAID Vaccine Res Ctr 9000 Rockville Pike Bethesda MD 20892 USA;

NIAID Vaccine Res Ctr 9000 Rockville Pike Bethesda MD 20892 USA;

Univ N Carolina Inst Global Hlth &

Infect Dis Chapel Hill NC 27515 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类 R23;
关键词

相似文献

外文文献
中文文献
专利

1. N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies [J] . Dezhi Li, Jie Liu, Li Zhang, 中国病毒学：英文版 . 2015,第006期
2. Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART [J] . Sharon A Riddler, Lu Zheng, Christine M Durand, Open Forum Infectious Diseases . 2018,第10期

机译：评估广泛中和的HIV-1单克隆抗体VRC01对有效ART的HIV-1持久性影响的随机临床试验
3. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. [J] . Choudhry V, Zhang MY, Sidorov IA, Virology . 2007,第1期

机译：交叉反应性HIV-1中和性单克隆抗体，可通过筛选针对人包膜糖蛋白（gp140）的免疫人噬菌体文库进行筛选，该包膜糖蛋白从具有广泛HIV-1中性抗体的患者（R2）中分离。
4. A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings [J] . Mgodi Nyaradzo M., Takuva Simbarashe, Edupuganti Srilatha, JAIDS: Journal of acquired immune deficiency syndromes . 2021,第1期

机译：第2B期研究，以评估VRCO1宽度中和单克隆抗体在撒哈拉以南妇女中获得HIV-1感染中的安全性和功效：基线调查结果
5. Structure-Guided Engineering of Broadly Neutralizing Antibodies Targeting the CD4 Binding Site of HIV-1 Envelope [C] . Yen-Ting Lai, Qingbo Liu, Peng Zhang, Protein Engineering Summit. . 2018

机译：靶向靶向HIV-1包络CD4结合位点的宽度中和抗体的结构引导工程
6. Two Sides to the Same Antibody: Assessing the Role of Neutralizing and Non-neutralizing Antibodies in Mother-to-child Transmission of HIV-1 [D] . Ghulam-Smith, Melissa 2021

机译：两侧到同一抗体：评估中和和非中和抗体在HIV-1的母儿传播中的作用
7. Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART [O] . Sharon A Riddler, Lu Zheng, Christine M Durand, 2018

机译：评估广泛中和的HIV-1单克隆抗体VRC01对个体HIV-1持久性有效ART的影响的随机临床试验
8. Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART [O] . Sharon A Riddler, Lu Zheng, Christine M Durand, 2018

机译：随机临床试验评估宽度中和HIV-1单克隆抗体VRC01对有效艺术中个体HIV-1持久性的影响
9. Plaque Transfer Assay for Detecting Neutralizing Antibodies to HTLV-III (AIDS). HIV-1 Inactivation by Antibodies: Predominance of a Group-Specific Epitope that Persists Despite Genetic Variation [R] . Berkower, I., Murphy, D. 1989

机译：用于检测HTLV-III（aIDs）的中和抗体的噬斑转移测定。抗体的HIV-1灭活：尽管存在遗传变异，但仍然存在的群特异性表位的优势

Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

摘要

著录项

相似文献

相关主题

期刊订阅